Breaking News Instant updates and real-time market news.

MRK

Merck

$75.58

-0.89 (-1.16%)

06:52
01/03/19
01/03
06:52
01/03/19
06:52

Merck receives five new approvals in Japan for Keytruda

Merck announced today that Keytruda, Merck's anti-PD-1 therapy, has simultaneously received five new approvals from the Japan Pharmaceuticals and Medical Devices Agency, or PMDA, including three expanded uses in advanced non-small lung cancer, or NSCLC, one in melanoma, as well as a new indication in advanced microsatellite instability-high, or MSI-H, tumors. The following new approvals were all granted priority review by the PMDA: Keytruda in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of unresectable, advanced/recurrent nonsquamous NSCLC regardless of PD-L1 expression. Keytruda in combination with carboplatin and paclitaxel or nab-paclitaxel for the first-line treatment of unresectable, advanced/recurrent squamous NSCLC regardless of PD-L1 expression. Keytruda monotherapy in the first-line treatment of PD-L1-positive unresectable, advanced/recurrent NSCLC. Keytruda monotherapy as adjuvant therapy for melanoma. Keytruda monotherapy for the treatment of advanced/recurrent MSI-H solid tumors that have progressed after chemotherapy, based on results of falco Biosystems, has also been approved. In addition to the adjuvant therapy approval, dosage and administration for all patients with melanoma has been changed from intravenous infusion of 2 mg/kg over 30 minutes at a three-week interval to intravenous infusion of the fixed dose of 200 mg over 30 minutes at a three-week interval. Previously, Keytruda was approved in Japan for the treatment of curatively unresectable melanoma; PD-L1-positive unresectable, advanced or recurrent NSCLC; relapsed or refractory classical Hodgkin lymphoma and curatively unresectable urothelial carcinoma that progressed after chemotherapy.

  • 11

    Jan

  • 28

    Jan

  • 16

    Feb

  • 11

    Apr

  • 18

    May

MRK Merck
$75.58

-0.89 (-1.16%)

11/19/18
WELS
11/19/18
NO CHANGE
WELS
Pfizer price hikes may bring industry scrutiny, says Wells Fargo
Pfizer's (PFE) plans to raise prices on a host of medicines may put the drug industry "further in the crosshairs of an administration and Congress that is set on lowering drug prices," Wells Fargo analyst David Maris tells investors in a research note. The analyst points out that Pfizer earlier this year was criticized by the Trump administration for drug price increases, and as a result, it rolled the price increases back. However, Pfizer's new price increases "are not egregious" and its advance warning may be an attempt to see if minor price increases will also bring the administration's rebuke, says Maris. Nonetheless, given how public the administration's previous rebuke was, the analyst thinks Pfizer's confirmation Friday could "enflame the debate around drug pricing, especially since it comes less than two weeks following an election that resulted in Democrat control of the House with many having run on a drug-price-controls/Medicare-for-All platforms." Other large drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
11/06/18
PIPR
11/06/18
NO CHANGE
Target $3
PIPR
Overweight
OncoSec price target lowered to $3 from $5 at Piper Jaffray
After OncoSec (ONCS) reported preliminary Phase 2b KEYNOTE-695 data for Tavo combined with Merck's (MRK) Keytruda in PD-1 refractory melanoma patients, Piper Jaffray analyst Edward Tenthoff said the data, while early, show evidence of clinical activity, adding that he believes duration of response data will be important. However, OncoSec shares are down 52% today, which Tenthoff attributes to the lower response rate compared to prior data in different patients. The analyst keeps an Overweight rating on OncoSec shares, but lowered his price target on the stock to $3 from $5 as he pushed out his approval projections for Tavo by one year in the U.S. and Europe.
10/31/18
SBSH
10/31/18
NO CHANGE
Target $84
SBSH
Buy
Merck price target raised to $84 from $79 at Citi
Citi analyst Andrew Baum raised his price target for Merck to $84 and reiterates a Buy rating on the shares. The analyst says his 20%-plus above consensus non-GAAP earnings estimates beyond 2022 are driven by a continued view that the market underestimates Merck's market share in the PDx and PARP spaces with Keytruda and Lynparza respectively.
10/25/18
WELS
10/25/18
NO CHANGE
WELS
Wells Fargo says Trump speech today won't be end of drug pricing proposals
Wells Fargo analyst David Maris notes that Politico and other media outlets are reporting that President Donald Trump will propose several new initiatives to address high drug prices when he speaks later today at the U.S. Department of Health and Human Services. Maris thinks Trump's focus will be on how other countries are "freeloading" on U.S. innovation with lower negotiated pricing, stating that news reports make it appear that the administration is targeting the industry for action, rather than other countries to raise their spending. While Maris acknowledges the timing of the speech being near the mid-term elections, he believes these proposals are simply the follow-though of earlier promises. He also expects this is not the end of proposals to address the issue of U.S. drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

TODAY'S FREE FLY STORIES

NJDCY

Nidec

$0.00

(0.00%)

08:57
11/14/19
11/14
08:57
11/14/19
08:57
Conference/Events
Nidec management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

LTRX

Lantronix

$3.15

0.06 (1.94%)

08:56
11/14/19
11/14
08:56
11/14/19
08:56
Conference/Events
Lantronix management to meet with Needham »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

LNDC

Landec

$10.86

0.195 (1.83%)

08:55
11/14/19
11/14
08:55
11/14/19
08:55
Conference/Events
Landec management to meet with Lake Street »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 15

    Nov

  • 15

    Nov

NETE

Net Element

$4.54

0.02 (0.44%)

08:55
11/14/19
11/14
08:55
11/14/19
08:55
Earnings
Net Element reports Q3 EPS (24c), one est. (13c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRRM

Verra Mobility

$14.70

0.045 (0.31%)

08:55
11/14/19
11/14
08:55
11/14/19
08:55
Syndicate
Verra Mobility 15M share Spot Secondary priced at $14.25 »

The deal range was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

DIS

Disney

$148.69

10.13 (7.31%)

, AAPL

Apple

$264.52

2.63 (1.00%)

08:55
11/14/19
11/14
08:55
11/14/19
08:55
Options
Notable open interest changes for November 14th »

Wednesday's total…

DIS

Disney

$148.69

10.13 (7.31%)

AAPL

Apple

$264.52

2.63 (1.00%)

CSCO

Cisco

$48.44

0.06 (0.12%)

AMD

AMD

$37.52

0.81 (2.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 12

    Feb

08:55
11/14/19
11/14
08:55
11/14/19
08:55
General news
U.S. equities are under modest downward pressure »

U.S. equities are under…

08:55
11/14/19
11/14
08:55
11/14/19
08:55
General news
Treasury Action: yields are unmoved by the data mix »

Treasury Action: yields…

08:55
11/14/19
11/14
08:55
11/14/19
08:55
General news
Breaking General news story  »

Federal Reserve Board of…

08:55
11/14/19
11/14
08:55
11/14/19
08:55
General news
Breaking General news story  »

Federal Reserve Board of…

08:55
11/14/19
11/14
08:55
11/14/19
08:55
General news
Breaking General news story  »

Chicago Federal Reserve…

GILT

Gilat Satellite

$7.42

-0.06 (-0.80%)

, ENT

Global Eagle

$0.55

-0.0416 (-7.05%)

08:53
11/14/19
11/14
08:53
11/14/19
08:53
Hot Stocks
Global Eagle places $5M order with Gilat's Wavestream for transceivers »

Gilat Satellite Networks…

GILT

Gilat Satellite

$7.42

-0.06 (-0.80%)

ENT

Global Eagle

$0.55

-0.0416 (-7.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

LNDC

Landec

$10.86

0.195 (1.83%)

08:53
11/14/19
11/14
08:53
11/14/19
08:53
Conference/Events
Landec management to meet with DA Davidson »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 15

    Nov

  • 15

    Nov

AAPL

Apple

$264.52

2.63 (1.00%)

08:53
11/14/19
11/14
08:53
11/14/19
08:53
Hot Stocks
Apple announces users can enroll in three health studies through Research app »

Apple announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIA

Viacom

$25.14

-0.615 (-2.39%)

, VIAB

Viacom

$22.04

-0.52 (-2.30%)

08:52
11/14/19
11/14
08:52
11/14/19
08:52
Hot Stocks
Viacom says Pluto TV has about 20M MAUs »

Viacom management sees…

VIA

Viacom

$25.14

-0.615 (-2.39%)

VIAB

Viacom

$22.04

-0.52 (-2.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

  • 09

    Dec

TSE

Trinseo

$44.56

-1.065 (-2.33%)

08:51
11/14/19
11/14
08:51
11/14/19
08:51
Downgrade
Trinseo rating change  »

Trinseo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TDOC

Teladoc

$79.66

-1.12 (-1.39%)

08:51
11/14/19
11/14
08:51
11/14/19
08:51
Hot Stocks
Teladoc earns two telehealth accreditations from ClearHealth Quality Institute »

Teladoc Health announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BASI

Bioanalytical Systems

$5.23

0.01 (0.19%)

08:50
11/14/19
11/14
08:50
11/14/19
08:50
Hot Stocks
Bioanalytical Systems launches rebrand of contract research services business »

Bioanalytical Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITT

ITT

$68.39

-0.23 (-0.34%)

08:49
11/14/19
11/14
08:49
11/14/19
08:49
Conference/Events
ITT management to meet with DA Davidson »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

ENR

Energizer

$48.35

6.34 (15.09%)

08:48
11/14/19
11/14
08:48
11/14/19
08:48
Recommendations
Energizer analyst commentary  »

Energizer price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

SNNA

Sienna Biopharmaceuticals

$0.16

-0.008 (-4.74%)

08:47
11/14/19
11/14
08:47
11/14/19
08:47
Hot Stocks
Sienna Biopharmaceuticals says Nasdaq panel grants request for continued listing »

Sienna Biopharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTNT

Fortinet

$99.69

-0.245 (-0.25%)

08:47
11/14/19
11/14
08:47
11/14/19
08:47
Conference/Events
Fortinet management to meet with MKM Partners »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 18

    Nov

  • 19

    Nov

  • 05

    Dec

  • 06

    Dec

  • 09

    Dec

  • 12

    Dec

PRSP

Perspecta

$27.79

-0.18 (-0.64%)

08:46
11/14/19
11/14
08:46
11/14/19
08:46
Hot Stocks
Perspecta Labs wins $6.6M award on DARPA GAPS program »

Perspecta announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRPT

Sarepta

$101.00

0.99 (0.99%)

08:45
11/14/19
11/14
08:45
11/14/19
08:45
Hot Stocks
Sarepta announces collaboration, license agreement with StrideBio »

arepta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XNET

Xunlei

$5.79

0.07 (1.22%)

, AMC

AMC Entertainment

$8.77

-0.51 (-5.50%)

08:45
11/14/19
11/14
08:45
11/14/19
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

XNET

Xunlei

$5.79

0.07 (1.22%)

AMC

AMC Entertainment

$8.77

-0.51 (-5.50%)

CGC

Canopy Growth

$18.52

-0.69 (-3.59%)

NLOK

NortonLifeLock

$24.57

0.36 (1.49%)

FB

Facebook

$193.20

-1.27 (-0.65%)

HGV

Hilton Grand Vacations

$35.24

-0.07 (-0.20%)

HEXO

Hexo

$1.99

-0.14 (-6.59%)

ADT

ADT Inc.

$8.36

0.66 (8.57%)

BUD

AB InBev

$79.37

0.28 (0.35%)

ABB

ABB

$21.93

0.11 (0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

  • 19

    Nov

  • 27

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.